Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody Sotigalimab (APX005M) With or Without Stereotactic Body Radiation Therapy in Adults With Unresectable or Metastatic Melanoma

NCT04337931 is registered in ClinicalTrials.gov with Apexigen America, Inc. as lead sponsor.

NCT NCT04337931
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04337931 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Multicenter, Open-label Study to Evaluate the Safety and Efficacy of the CD40 Agonistic Antibody Sotigalimab (APX005M) With or Without Stereotactic Body Radiation Therapy in Adults With Unresectable or Metastatic Melanoma
Lead sponsor
Apexigen America, Inc.
Phase
Phase 2
Overall status
Terminated
Start date
June 12, 2019
Completion date
August 2, 2022
Enrollment
45 (actual)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, cancer of skin, melanoma, melanoma (skin), metastatic melanoma, unresectable melanoma